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Abstract
Background: A multi-institutional phase II study was conducted to evaluate the efficacy and safety
of preoperative docetaxel, cisplatin and S-1 therapy in marginally resectable advanced gastric
cancer.
Methods: Patients with macroscopic type 4, large macroscopic type 3 and bulky lymph node
metastasis received two cycles of preoperative docetaxel, cisplatin and S-1 therapy (docetaxel
40 mg/m2 and cisplatin 60 mg/m2 on day 1, and S-1 80 mg/m2 for 14 days, every 4 weeks). The
primary endpoint was the pathological response rate, with an expected value of 65%.
Results: Thirty-one patients were enrolled in this study. The pathological response rate was 54.8%,
and it was higher than the threshold value but lower than the expected rate. The R0 resection rate
was 93.5%. The frequencies of grade 3–4 toxicities during docetaxel, cisplatin and S-1 therapy were
41.9% for neutropenia, 6.5% for febrile neutropenia and 32.3% for nausea/vomiting. Grade 2 and 3
surgical morbidities occurred in 23.3 and 6.7% of the patients, respectively.
Conclusions: Preoperative docetaxel, cisplatin and S-1 therapy was feasible in terms of
chemotherapy-related toxicities and surgical morbidity, but the effect did not achieve the expected
value. The association between the pathological response rate and survival will be evaluated in the
final analysis of this clinical trial.
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Introduction
Gastric cancer is the fifth most common cancer and the third leading
cause of cancer-related mortality. An estimated 1033 700 new gastric
cancer cases and 782 700 deaths occurred (1). Curative resection with
perioperative adjuvant treatment is the standard treatment for locally
advanced gastric cancer worldwide (2). In Asia, D2 gastrectomy and
postoperative adjuvant chemotherapy with S-1, S-1 and docetaxel, or
capecitabine and oxaliplatin is the standard treatment (3). However,
the recurrence rate was reported to 30–40%, even after curative
treatment. In addition, it was previously reported that macroscopic
type 4, large (diameter >8 cm) macroscopic type 3, and bulky lymph
node metastasis have been reported as prognostic factors in locally
advanced gastric cancer (4,5). Aggressive treatment is needed to
improve the survival of patients with locally advanced gastric cancer
who have risk factors for severe disease.
Curative resection and perioperative chemotherapy are widely
accepted treatments in Europe (6). Theoretically, preoperative
(neoadjuvant) chemotherapy has some clinical benefits in compari-
son to postoperative chemotherapy (7). Preoperative chemotherapy
might be able to eliminate micrometastasis and improve chemother-
apy compliance in comparison to postoperative chemotherapy.
However, the optimal regimen and duration are unclear.
Among several promising regimens, combination treatment with
docetaxel, cisplatin and S-1 (DCS) had received attention for its
efficacy and safety in patients with metastatic gastric cancer (8,9)
until the JCOG 1013 study denied the superiority of DCS therapy
over cisplatin plus S-1 (CS) therapy in 2019 (10). Based on this
background, we conducted a multi-institutional phase II trial of
preoperative chemotherapy with DCS to evaluate the efficacy and
safety in gastric cancer patients with type 4 tumors, large type 3
tumors or bulky lymph node metastasis.
The present study evaluated the efficacy of preoperative DCS
therapy. The primary endpoint was the pathological response rate
(pRR), and the secondary endpoints were chemotherapy-related
toxicities, morbidity and mortality as short-term outcomes and the
overall and relapse-free survival as long-term outcomes. This report
clarified the impact of DCS on short-term endpoints.
Patients and methods
Eligibility criteria
Tumors were staged according to the 13th edition of the Japanese
Gastric Cancer Classification (11). However, in this paper, we trans-
lated the stages to the 14th edition (12), which was integrated with
the 7th edition of AJCC cancer staging (13). The eligibility criteria
were as follows: (i) histologically proven gastric adenocarcinoma, (ii)
macroscopic type 4, large (major axis >8 cm) macroscopic type 3, or
bulky lymph node metastasis (one lymph node ≥3 cm or two adjacent
lymph nodes ≥1.5 cm along the celiac, common or proper hepatic,
or splenic arteries), (iii) macroscopically resectable gastric cancer
without distant metastasis diagnosed by thoracic/abdominal/pelvic
computed tomography and staging laparoscopy, (iv) esophageal inva-
sion <3 cm, (v) age 20–80 years, (vi) Eastern Cooperative Oncol-
ogy Group performance status 0–1, (vii) no previous history of
chemotherapy or radiation therapy for any other cancer, and no
previous history of surgery for gastric cancer, with the exception
of bypass surgery, (viii) an adequate organ function (white blood
cell [WBC] count ≥3000/mm3 and ≤12 000/mm3; hemoglobin level
≥9.0 g/dl; platelet count ≥100 000/mm3; aspartate aminotransferase
[AST] and alanine aminotransferase [ALT] levels ≤2.5x the upper
limit of normal [ULN]; total bilirubin level ≤1.5 mg/dL; creatinine
≤1.5 mg/dL and creatinine clearance ≥60 ml/min/body in the Cock-
croft–Gault equation) and (ix) written informed consent.
The exclusion criteria were as follows: (i) synchronous or
metachronous cancer within 5 years, (ii) severe co-morbidities, (iii)
pregnant or lactating woman, (iv) severe mental disease that might
hinder participation in this study or (v) physician judged that the
patient would be unable to complete the protocol treatment.
Preoperative chemotherapy
We adopted the DCS regimen reported by Koizumi et al. (9) because
of its low toxicity and high response rate among various DCS
regimens. Docetaxel (40 mg/m2) and cisplatin (60 mg/m2) were
administered by intravenous infusion on day 1 of each cycle, and S-1
(80 mg/m2) was given orally for the first 14 days of a 28-day cycle.
After the completion of two cycles of chemotherapy or when the con-
tinuation of chemotherapy was difficult, the possibility of curative
resection was evaluated. If macroscopically curative resection was
considered possible, the patients underwent surgery within 42 days
after the last administration of S-1.
Chemotherapy-related toxicities were evaluated according to the
Common Terminology Criteria for Adverse Events, version 3.0. The
subsequent chemotherapy cycle was delayed until patient recovery,
including the following parameters: WBC count ≥3000/mm3; neu-
trophil count ≥1500/mm3; platelet count ≥100 000/mm3; AST and
ALT levels ≤2.5x ULN; total bilirubin level ≤1.5x ULN; creatinine
level ≤1.5 mg/dL and creatinine clearance ≥60 ml/min/body; diar-
rhea or stomatitis grade ≤1; and other non-hematological adverse
event grade ≤2. The DCS doses were reduced in the event of
a WBC count ≤1000/mm3; neutrophil count ≤500/mm3; platelet
count ≤50 000/mm3; or grade ≥3 non-hematological adverse events.
Surgery and adjuvant chemotherapy
After laparotomy, intraperitoneal lavage cytology was examined.
Regardless of the results of cytology, gastrectomy with D2 lymph
node dissection was performed if macroscopic curative resection was
possible without obvious residual cancer. Laparoscopic gastrectomy
was not allowed, and combined resection of the surrounding organs
was allowed if R0 resection was considered possible. If curative
resection was considered impossible due to factors other than posi-
tive lavage cytology, the protocol treatment was terminated. Surgical
morbidities were evaluated by the Clavien–Dindo classification (14)
in this analysis.
Adjuvant chemotherapy with S-1 was started within 42 days
after surgery for patients who underwent R0 resection or R1 resec-
tion with positive lavage cytology. The oral administration of S-1
(80 mg/m2) for 28 days followed by 14 days rest was continued for
1 year after surgery.
Study design and statistical methods
This study was designed to evaluate the efficacy and safety of
preoperative DCS therapy in patients with locally advanced gastric
cancer. The primary endpoint was the pRR, and the secondary end-
points were chemotherapy-related toxicities, morbidity and mortality
as short-term outcomes and the overall and relapse-free survival
as long-term outcomes. Because the required follow-up period has
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Figure 1. Flow diagram of the present study.
The pathological response of resected specimens was graded by
a histopathologist according to the 13th edition of the Japanese
classification of gastric carcinoma as follows: grade 0, no evidence
of effect; grade 1a, viable tumor cells occupy ≥2/3 of the tumorous
area; grade 1b, viable tumor cells remaining in ≥1/3 but <2/3; grade
2, viable tumor cells remaining in <1/3; grade 3, no viable tumor
cells remaining (11). All cases were diagnosed by a pathologist
at each institution who had a specialist qualification from the
Japanese Society of Pathology. A grade 1b-3 response was defined
as a positive pathological response in this study. The clinical
response was evaluated by the Response Evaluation Criteria in Solid
Tumor version 1.0 (15), and the disease control rate was defined
as the sum of the complete response, partial response and stable
disease rates.
The pRR of preoperative chemotherapy with CS for type 4
tumors or large type 3 tumors in JCOG 0210 and for bulky or
paraaortic lymph node metastasis in JCOG 0405 were 49 and 51%,
respectively (16,17). DCS therapy was expected to be more effective
but more toxic than CS therapy. Based on these data, we calculated
that the required number of patients was 25 patients, assuming that
the threshold and expected pRR were 40 and 65%, respectively,
with a one-sided α error of 0.05 and a β error of 0.2. Considering
the possibility of dropouts and ineligible patients, 30 patients were
required.
The protocol of this study was approved by the proto-
col review committee of Yokohama City University (approved
number: B09003120025) and each participating institution,
in accordance with the ethical standards prescribed by the
Helsinki Declaration. This study was registered at the Univer-




Between August 2008 and May 2016, 31 patients from three
institutions were enrolled in this study. Figure 1 shows the
flow diagram of this study, and Table 1 shows the patient and
tumor characteristics. All patients underwent staging laparoscopy
before enrollment, with 29 patients having P0CY0 and 2 having
P0CY1. The rate of completion of preoperative chemotherapy was
80.6% (25 of 31). Preoperative chemotherapy was discontinued
in five patients (16.1%) due to adverse events. Thirty patients
received D2 gastrectomy. One patient did not proceed to surgery
due to progression of metastatic lymph node disease during










ospital user on 20 April 2021
374 Preoperative DCS therapy for gastric cancer
Table 1. Patient and tumor characteristics according to the 14th edition of Japanese classification of gastric carcinoma
Characteristic Variable Number of patients (n = 31) (%)
Age (years) Median 69
Range 52–78
Gender Male/Female 23/8 74.2/25.8
PS 0/1 28/3 90.3/9.7
Macroscopic type Type 3 25 80.6
Type 4 5 16.1
Others 1 3.2
Histological type Differentiated 12 38.7
Undifferentiated 19 61.3








CY factor CY0 29 93.5
CY1 2 6.5
Clinical M factor M0 29 93.5
M1 2 6.5
Clinical Stage Stage IA 0 0.0
Stage IB 1 3.2
Stage IIA 0 0.0
Stage IIB 1 3.2
Stage IIIA 15 48.3
Stage IIIB 12 38.7
Stage IIIC 0 0.0
Stage IV 2 6.5
PS: performance status; CY: peritoneal lavage cytology
Table 2. Pathological response of the primary tumors
Characteristics Number of patients
(n = 31)
(%)
Grade 0 2 6.4
Grade 1a 11 35.5
Grade 1b 10 32.3
Grade 2 6 19.4
Grade 3 1 3.2
Unresected 1 3.2
Response
Table 2 shows the pRR of the primary tumors. A pathological
response, defined as a complete response or <2/3 residual cancer
cells (grade 1b-3), was 54.8% (17 of 31). The pathological complete
response rate (grade 3) was 3.2% (1 of 31).
Chemotherapy-related Toxicities
Table 3 shows the details of preoperative chemotherapy-related tox-
icities. The incidence of grade 3 or 4 toxicities was high for leukope-
nia, neutropenia, and nausea/vomiting. However, the incidence of
febrile neutropenia (FN) was relatively low and there were no
chemotherapy-related deaths. The actual total dose of each drug that
was administered is shown in Table 4.
Surgery
Table 5 shows the details of the surgical procedures that were per-
formed. The proximal margin was positive in one patient, but no
additional treatment was given because of the patient’s refusal. D2
lymph node dissection was performed in all patients, but there
were no patients who underwent extended lymph node dissection.
Intraperitoneal lavage cytology was negative in all patients, including
two patients in whom lavage cytology changed from positive to
negative after preoperative chemotherapy. The R0 resection rate was
93.5% (29 of 31). Grade 2 surgical morbidities were observed in five
(16.7%) patients, and grade 3a surgical morbidities were observed in
two (6.7%) patients. No patients required reoperation for morbidity
or surgical mortality. The details of the postoperative complications
are shown in Table 6, and the details of the pathological findings are
shown in Table 7.
Postoperative chemotherapy
Postoperative adjuvant chemotherapy with S-1 was adminis-
tered to 27 of the 29 patients who underwent R0 resection.
Two patients with R0 resection and 1 with R1 refused addi-
tional treatment (Figure 1). Of the 27 patients who received
postoperative adjuvant chemotherapy, 13 (48.1%) completed
postoperative chemotherapy with S-1 for 1 year, whereas 8
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Table 3. Adverse events related to preoperative chemotherapy
Adverse event Grade 3/4 All grade
Number of patients (%) Number of patients (%)
Hematological
Leukopenia 7 22.5 20 64.5
Neutropenia 13 41.9 23 74.2
Anemia 4 12.9 21 67.7
Thrombocytopenia 1 3.2 3 9.7
Febrile neutropenia 2 6.5 2 6.5
No hematological
Elevated AST 0 0.0 7 22.6
Elevated ALT 0 0.0 9 29.0
Elevated serum Bil 0 0.0 1 3.2
Elevated creatine 0 0.0 11 35.5
Nausea/Vomiting 10 32.3 29 93.5
Diarrhea 3 9.7 14 45.2
Rash 0 0.0 0 0.0
Fatigue 3 9.7 26 83.9
Alopecia 0 0.0 26 83.9
Thromboembolism 1 3.2 1 3.2
Infusion related reaction 0 0.0 0 0.0
Paresthesia 0 0.0 0 0.0
AST: Aspartate transaminases; ALT: Alanine aminotransferase; Bil: Bilirubin.
Table 4. Actual total dose administered
Treatment parameter S-1 Cisplatin Docetaxel
Mean 82.5% 86.5% 88.0%
≥90% 19 21 21
≥80 to <90% 3 2 3
≥60 to <80% 3 2 0
<60% 6 6 7
Table 5. Surgical outcomes
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Table 6. Postoperative complications
All grades (%) Grade 3a (%)
Postoperative bleeding 1 3.3 0 0.0
Anatomic leakage 1 3.3 0 0.0
Pancreatic fistula 1 3.3 1 3.3
Intra-abdominal abscess 1 3.3 1 3.3
Wound infection 0 0.0 0 0.0
Ileus 1 3.3 0 0.0
Anatomic stenosis 1 3.3 0 0.0
Pneumothorax 1 3.3 1 3.3
Pneumonia 2 6.7 0 0.0
Table 7. Pathological findings according to the 14th edition of Japanese classification of gastric carcinoma
Characteristic Variable Number of patients (n = 30) (%)











Number of resected lymph nodes Median 38
Range 22–72
CY factor CY0 30 100.0
CY1 0 0.0
Pathological M factor M0 30 100.0
M1 0 0.0
Pathological stage ypStage 0 1 3.3
ypStage IA 3 10.0
ypStage IB 1 3.3
ypStage IIA 6 20.0
ypStage IIB 2 6.7
ypStage IIIA 7 23.3
ypStage IIIB 4 13.3
ypStage IIIC 6 20.0
ypStage IV 0 0.0
CY: peritoneal lavage cytology
Discussion
The aim of the present study was to evaluate the efficacy and
safety of preoperative chemotherapy with DCS in patients with
marginally resectable advanced gastric cancer, including patients with
type 4 tumors, larger type 3 tumors or bulky lymph node metastasis.
Although the chemotherapy-related toxicities and surgical complica-
tions as secondary endpoints were feasible, the pRR as the primary
endpoint was higher than the threshold value but lower than the
expected rate. These results suggested that our DCS regimen was
less toxic but not sufficiently effective to justify proceeding to a
phase III trial.
The most likely reason why our DCS regimen failed to achieve
the primary endpoint was that the total dose was insufficient. DCS
regimens with higher and lower doses have been reported for unre-
sectable advanced gastric cancer, with the higher-dose regimen being
more effective but more toxic and the lower-dose regimen being less
toxic (8,9). In Japan, several phase II trials have been conducted to
identify the optimal dosage of DCS for preoperative chemotherapy
(18–21). Each study had different eligibility criteria and primary
endpoints. Among the studies of preoperative low-dose DCS therapy,
we first set the pRR as the primary endpoint. This was not a
common approach at the time, as we did not have sufficient evidence
regarding the pathological response, but a recent study showed that
the pRR was an excellent surrogate endpoint for the overall survival
in studies of preoperative chemotherapy (22). The doses of each drug
in this study were as follows: docetaxel, 10 mg/m2/week; cisplatin,
15 mg/m2/week and S-1, 280 mg/m2/week. On the other hand, a
representative high-dose regimen reported by Hirakawa et al. (18)
was composed of docetaxel 20 mg/m2/week, cisplatin 20 mg/m2/week
and S-1 373 mg/m2/week. Recently, the pRR of other studies of
preoperative DCS therapy was reported to be 50–57% in the lower-
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The pRR in this study was 54.8%. Similar pRRs were observed in
other studies with low-dose DCS regimens. We speculate that this
supports the hypothesis that the pRR is associated with the dose of
chemotherapy.
The feasibility of two-course chemotherapy was also controver-
sial in terms of the total dose. In this study, patients received two
courses of preoperative DCS therapy. In the KDOG 1001 study,
which used the same doses as this study, the overall pRR was 57.5%,
but it was higher (69.5%) in patients who received four courses (20).
However, according to their protocol, it was possible to administer
up to four courses if a good response was obtained. This may indicate
that patients who had already shown a histological response by the
second course received four courses of chemotherapy. Meanwhile,
Aoyama et al. (21) reported that the pRR of four courses of DCS
therapy did not differ from that of two courses, according to the
results of a phase II trial comparing neoadjuvant chemotherapy with
two and four courses for locally advanced gastric cancer. Considering
these reports, more careful discussion is needed to increase the
number of courses of preoperative chemotherapy.
In this study, chemotherapy-related toxicities were relatively mild.
In particular, the incidence of FN was 6.5%, which was similar
to the results of the JCOG 1002 (5.7%) and KDOG 1001 (7.5%)
trials, which used the same dosing regimen as this study (19,20).
Conversely, the incidence of FN in patients treated with higher-dose
DCS therapy was reported to be 16.3% (18). Generally, FN requires
a long time to recover, and the long chemotherapy-free interval may
help tumor progression and prevent subsequent surgery. Fortunately,
gastrectomy was performed in 30 of 31 patients (96.8%) in the
present study, with one patient unable to undergo gastrectomy due
to tumor progression.
Postoperative complications have been reported to have a nega-
tive impact on the long-term survival (23). The frequency of postop-
erative complications of ≥ grade 3 has been reported to be 8.3–12%
in previous studies of doublet preoperative chemotherapy (16,17).
There was a concern that postoperative complications would increase
because this study adopted a triplet regimen. However, the actual
incidence of grade ≥2 and ≥3 postoperative complications in this
study was 23.3 and 6.7%, respectively, and there was no surgical
mortality. We hypothesize that in addition to the administration of
a low-dose regimen, the volume reduction induced by preoperative
chemotherapy contributed to the safety.
The present study was associated with some limitations. First,
this was a single-arm phase II study and evaluated only early end-
points, including the pathological response, chemotherapy-related
toxicities, and surgical results. Second, the pRR was determined
by the pathologist at each institution and there was no central
assessment. Third, the low incidence of postoperative complications
may reflect the difficulty of the surgical procedure rather than
the impact of the intensity of preoperative chemotherapy. In this
study, none of the patients required extended lymph node dissec-
tion, even though patients with marginally resectable cancer were
included.
In conclusion, preoperative DCS therapy was feasible in terms of
chemotherapy-related toxicities and surgical morbidity; however, the
effect did not achieve the expected value. The association between
the pRR and survival will be evaluated in the final analysis of this
clinical trial.
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